Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670306 · ClinicalTrials.gov registry record · Phase 3
Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
A Phase 3 study of Benign Prostatic Hypertrophy, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 3
- Development phase
- 528
- Enrollment target
- 20
- Study locations
NCT00670306 is a Phase 3 study of Benign Prostatic Hypertrophy that has completed, run by AEterna Zentaris. The registered enrollment target is 528 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT00670306, a Phase 3 study of Benign Prostatic Hypertrophy, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 528 participants
- Enrollment target
- 20
- Study locations
Study Summary
Benign Prostatic Hyperplasia (BPH) is the most common hyperplastic disease occuring in human males over the age of 50 which increases in prevalence with age and 40% of males reported moderate or severe urinary symptoms of prostatism by the age of 50 to 80. The purpose of this study is to collect safety and efficacy data for this dosage regimen of cetrorelix pamoate. For this study, study medication (Cetrorelix pamoate) is administered by injection in the buttocks (Intramuscular).
Conditions Studied
Interventions
- DRUG Cetrorelix Pamoate
Study Locations (20)
California
- South Orange County Medical Research Center - Laguna Hills
- California Professionnal Research - Newport Beach
- Northern California Research - Sacramento
- San Diego Uro Research - San Diego
- Medical Center for Clinical Research - San Diego
- West Coast Clinical Research - Tarzana
Florida
- South Florida Medical Research - Aventura
- Tampa Bay Medical Research - Clearwater
- University Urologists - Lake Worth
- Specialists in Urology - Naples
- Winter Park Urology - Orlando
- Florida Urology Specialists - Sarasota
Alabama
- Urology Centers of Alabama - Homewood
- Medical Affiliated Research Center, Inc. - Huntsville
Connecticut
- Connecticut Clincal Research Center, LLC - Middlebury
- Urological Associates of Bridgeport - Trumbull
Colorado
- Genitourinary Surgical Consultants - Denver
Georgia
- Mount Vernon Clinical Research, LLC - Sandy Springs
Idaho
- North Idaho Urology - Coeur d'Alene
Indiana
- Northeast Indiana Research, LLC - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 528 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00670306
The ClinicalTrials.gov registry entry for NCT00670306 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 528 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Benign Prostatic Hypertrophy appearing as the primary indexed condition, and to 1 intervention - of which Cetrorelix Pamoate is the first listed.
NCT00670306 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00670306 about?
NCT00670306 is a clinical study titled "Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)". Benign Prostatic Hyperplasia (BPH) is the most common hyperplastic disease occuring in human males over the age of 50 which increases in prevalence with age and 40% of males reported moderate or severe urinary symptoms of prostatism by the age of 50 to 80. The purpose of this study is to collect saf...
What is the current status of trial NCT00670306?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 528 participants. The study started on 2008-03. Estimated completion is 2009-08.
What conditions does trial NCT00670306 study?
This clinical trial studies the following conditions: Benign Prostatic Hypertrophy.
What interventions are being tested in trial NCT00670306?
The interventions under investigation include: Cetrorelix Pamoate (DRUG).
Who is sponsoring clinical trial NCT00670306?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00670306 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hypertrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.